NCT05403242View on ClinicalTrials.gov

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Advanced Gastroesophageal Adenocarcinoma
Interventions
DRUG

RC48-ADC

2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks

DRUG

S-1

40-60 mg, bid po, d1-10, every 2 weeks

Trial Locations (3)

Unknown

RECRUITING

Beijing Friendship Hospital, Beijing

RECRUITING

Chinese PLA General Hospital, Beijing

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER